Share

August 2015; 2 (4) Views & ReviewsOpen Access

Aquaporin-4 autoimmunity

Anastasia Zekeridou, Vanda A. Lennon
First published May 21, 2015, DOI: https://doi.org/10.1212/NXI.0000000000000110
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
4157

Share

Article Information

vol. 2 no. 4 e110
DOI: 
https://doi.org/10.1212/NXI.0000000000000110
PubMed: 
26185772
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received December 17, 2014
  • Accepted in final form March 23, 2015
  • First Published May 21, 2015.
Copyright & Usage: 
© 2015 American Academy of Neurology This is an open access article distributed under the terms of the Creative Commons Attribution-Noncommercial No Derivative 4.0 License, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.

Author Disclosures

    1. Anastasia Zekeridou, MD and
    2. Vanda A. Lennon, MD, PhD
  1. Anastasia Zekeridou, MD and
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Vanda A. Lennon, MD, PhD
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. Dr. Lennon and Mayo Clinic have a financial interest in the following intellectual property: “Marker for Neuromyelitis Optica.” A patent has been issued for this technology, and it has been licensed to commercial entities. They have received cumulative royalties of greater than the federal threshold for significant financial interest from the licensing of these technologies. The author receives no royalties from the sale of these tests by Mayo Medical Laboratories; however, Mayo Collaborative Services, Inc. does receive revenue for conducting these tests.

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. The Mayo Neuroimmunology Laboratory performs service testing for aquaporin-4 autoantibodies on behalf of Mayo Collaborative Service Inc., an agency of Mayo Foundation. Dr. Lennon does not benefit financially from this testing.

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NIH R01-NS065829,?CNS Demyelinating Autoimmunity Targeting Water Channel Complexes?. Principal Investigator: S.J. Pittock Co-Investigator: V.A. Lennon Years: 2010-2015

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. “Marker for Neuromyelitis Optica”. A patent has been issued to Mayo Foundation for this technology, and it has been licensed to RSR/Kronus. Dr. Lennon has received cumulative royalties of greater than the federal threshold for significant financial interest from the licensing of these technologies.

    Royalty Payments, Technology or Inventions:

    1. Dr. Lennon has a potential financial interest in the technologies listed below: “Marker for Neuromyelitis Optica”.

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Departments of Laboratory Medicine and Pathology (A.Z., V.A.L.), Neurology (V.A.L.), and Immunology (V.A.L.), Neuroimmunology Laboratory, Mayo Clinic College of Medicine, Rochester, MN.
  1. Correspondence to Dr. Lennon: lennon.vanda{at}mayo.edu
View Full Text

Article usage

Article usage: May 2015 to August 2023

AbstractFullPdfSource
May 20151223430Highwire
Jun 201530018974Highwire
Jul 2015266165111Highwire
Jul 20150170106pmc
Aug 201550462191Highwire
Aug 20150213150pmc
Sep 20151254734Highwire
Sep 20150173132pmc
Oct 20151063528Highwire
Oct 2015011289pmc
Nov 2015791617Highwire
Nov 2015011787pmc
Dec 20151051525Highwire
Dec 201507456pmc
Jan 2016963117Highwire
Jan 201608461pmc
Feb 2016781829Highwire
Feb 201607954pmc
Mar 2016601616Highwire
Mar 201605235pmc
Apr 201647720Highwire
Apr 201607457pmc
May 20165477Highwire
May 201606849pmc
Jun 201633105Highwire
Jun 201605442pmc
Jul 20163657Highwire
Jul 201605428pmc
Aug 201636106Highwire
Aug 201605334pmc
Sep 20162696Highwire
Sep 201604629pmc
Oct 201633146Highwire
Oct 201603925pmc
Nov 2016621522Highwire
Nov 201604217pmc
Dec 2016291716Highwire
Dec 201602510pmc
Jan 2017461411Highwire
Jan 201703622pmc
Feb 201735108Highwire
Feb 201703413pmc
Mar 2017371910Highwire
Mar 201704725pmc
Apr 20172295Highwire
Apr 2017122224pmc
May 20172449Highwire
May 2017133636pmc
Jun 201736411Highwire
Jun 2017121921pmc
Jul 201718312Highwire
Jul 2017132833pmc
Aug 2017291410Highwire
Aug 201781720pmc
Sep 201720127Highwire
Sep 2017152942pmc
Oct 20172134Highwire
Oct 201792328pmc
Nov 20172748Highwire
Nov 2017113032pmc
Dec 201710428Highwire
Jan 20183339Highwire
Feb 201865212Highwire
Mar 2018410321Highwire
Apr 2018212418Highwire
Apr 2018102833pmc
May 2018212914Highwire
Jun 2018417911Highwire
Jun 201893031pmc
Jul 2018010020Highwire
Aug 2018710812Highwire
Aug 2018103443pmc
Sep 201868415Highwire
Oct 201829919Highwire
Nov 2018318211Highwire
Dec 20181129810Highwire
Jan 2019693129Highwire
Feb 20199145230Highwire
Mar 20199119139Highwire
Apr 20191394234Highwire
May 20191349440Highwire
Jun 2019938043Highwire
Jul 2019636715Highwire
Aug 2019818620Highwire
Sep 2019624621Highwire
Oct 20191216222Highwire
Nov 2019713616Highwire
Dec 201956720Highwire
Jan 202087823Highwire
Feb 202016914Highwire
Mar 2020810725Highwire
Apr 202029835Highwire
May 2020410626Highwire
Jun 202068520Highwire
Jul 2020211521Highwire
Aug 202039224Highwire
Sep 2020313241Highwire
Oct 2020513517Highwire
Nov 2020510638Highwire
Dec 202067220Highwire
Jan 2021139033Highwire
Feb 202148820Highwire
Mar 20211013344Highwire
Apr 2021611645Highwire
May 2021824333Highwire
Jun 2021713624Highwire
Jul 20211315151Highwire
Aug 2021418126Highwire
Sep 2021819527Highwire
Oct 2021519056Highwire
Nov 2021511942Highwire
Dec 2021716922Highwire
Jan 2022319229Highwire
Feb 2022522328Highwire
Mar 20221134776Highwire
Apr 2022720436Highwire
May 2022921349Highwire
Jun 20221424943Highwire
Jul 2022530940Highwire
Aug 2022946217Highwire
Sep 20221746155Highwire
Oct 20221230529Highwire
Nov 20221236137Highwire
Dec 20221017529Highwire
Jan 20231123429Highwire
Feb 20231325632Highwire
Mar 20231424439Highwire
Apr 20231316233Highwire
May 2023913522Highwire
Jun 20231016018Highwire
Jul 2023914418Highwire
Aug 20231510636Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Topics Discussed

Alert Me

Recommended articles